High Gross MarginA gross margin of ~69% provides a durable structural cushion versus peers, implying product or cost advantages on core offerings. Sustained high gross margins give management flexibility to invest in R&D and commercialization while dampening the revenue growth needed to approach operating profitability over time.

Very Low Financial LeverageExtremely low leverage and a strong equity ratio reduce solvency risk and preserve strategic optionality through clinical cycles. This structural balance-sheet strength supports access to capital, strategic partnerships, and cushioning against development setbacks without urgent refinancing pressure.

Diversified Revenue/funding ModelA business model that includes licensing, milestone payments, royalties, and grants distributes commercial risk and provides non-dilutive funding pathways. Structurally, this reduces dependency on product sales timing and enables capital-efficient advancement of the pipeline through partnerships and staged payments.

Bears Say

Persistent Negative ProfitabilityOngoing net losses and negative operating margins indicate the core business is not yet self-sustaining. Over the medium term the company must either achieve sustained positive operating leverage or secure repeated external funding, otherwise cash burn will constrain R&D and commercialization plans.

Negative Free Cash FlowNegative free cash flow limits the firm's ability to internally fund trials and commercialization costs, forcing reliance on equity or partnership financing. While improvement is positive, durable operational health requires consistent positive FCF to reduce dilution risk and finance long-term growth.

Unprofitable With No Dividend SupportBeing unprofitable removes earnings-derived resilience and eliminates dividend income as investor support. Structurally this heightens dependence on capital markets and strategic deals for runway, increasing dilution and execution risk if clinical or commercialization milestones slip.

RELIEF THERAPEUTICS Holding News

MindMaze Wins Baader Bank Coverage With Buy Rating, Boosting Market Visibility

The latest announcement is out from RELIEF THERAPEUTICS Holding ( ($CH:MMTX) ). MindMaze Therapeutics has gained additional visibility...

5d ago

MindMaze Names New CEO to Drive U.S. Expansion and Scale AI Neurotherapies

RELIEF THERAPEUTICS Holding ( ($CH:MMTX) ) has shared an update. MindMaze Therapeutics has appointed healthtech veteran Zach Henderson...

12d ago

MindMaze maps post-listing push to scale digital neurotherapies in U.S. and Europe

RELIEF THERAPEUTICS Holding ( ($CH:MMTX) ) just unveiled an announcement. MindMaze Therapeutics has outlined its post-listing strategy, highlighting...

21d ago

MindMaze Sets Global Reimbursement Framework to Scale AI-Powered Neurorehabilitation

RELIEF THERAPEUTICS Holding ( ($CH:MMTX) ) has issued an update. MindMaze Therapeutics has detailed a coordinated global reimbursement...

3M ago

MMTX FAQ

What was Relief Therapeutics Holding Ag’s price range in the past 12 months?

Relief Therapeutics Holding Ag lowest stock price was CHF0.41 and its highest was CHF4.49 in the past 12 months.

What is Relief Therapeutics Holding Ag’s market cap?

Relief Therapeutics Holding Ag’s market cap is CHF64.22M.

When is Relief Therapeutics Holding Ag’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Relief Therapeutics Holding Ag’s earnings last quarter?

Currently, no data Available

Is Relief Therapeutics Holding Ag overvalued?

According to Wall Street analysts Relief Therapeutics Holding Ag’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Relief Therapeutics Holding Ag pay dividends?

Relief Therapeutics Holding Ag does not currently pay dividends.

What is Relief Therapeutics Holding Ag’s EPS estimate?

Relief Therapeutics Holding Ag’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Relief Therapeutics Holding Ag have?

Relief Therapeutics Holding Ag has 159,102,450 shares outstanding.

What happened to Relief Therapeutics Holding Ag’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Relief Therapeutics Holding Ag?

Currently, no hedge funds are holding shares in CH:MMTX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Relief Therapeutics Holding Ag

MindMaze Therapeutics Holding SA develops and operates the MindMaze platform that integrates neuroscience and digital therapeutics to address some of the most pressing challenges in neurology. MindMaze Therapeutics Holding SA was formerly known as NeuroX Group SA. The company was incorporated in 2025 and is based in Lausanne, Switzerland.

Options Prices

Currently, No data available

---

Popular Stocks